We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exploring Analyst Estimates for Phreesia (PHR) Q2 Earnings, Beyond Revenue and EPS
Read MoreHide Full Article
Wall Street analysts forecast that Phreesia (PHR - Free Report) will report quarterly loss of -$0.07 per share in its upcoming release, pointing to a year-over-year increase of 77.4%. It is anticipated that revenues will amount to $116.45 million, exhibiting an increase of 14% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
In light of this perspective, let's dive into the average estimates of certain Phreesia metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts expect 'Revenus- Subscription and related services' to come in at $55.27 million. The estimate indicates a change of +13.7% from the prior-year quarter.
It is projected by analysts that the 'Revenus- Network solutions' will reach $33.25 million. The estimate points to a change of +17.9% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Revenus- Payment processing fees' of $27.90 million. The estimate points to a change of +10.3% from the year-ago quarter.
The consensus estimate for 'Average healthcare services Clients' stands at 4,475 . Compared to the present estimate, the company reported 4,169 in the same quarter last year.
Analysts predict that the 'Patient payment volume' will reach $1.18 billion. Compared to the present estimate, the company reported $1.09 billion in the same quarter last year.
Shares of Phreesia have demonstrated returns of +20.7% over the past month compared to the Zacks S&P 500 composite's +1.9% change. With a Zacks Rank #3 (Hold), PHR is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Exploring Analyst Estimates for Phreesia (PHR) Q2 Earnings, Beyond Revenue and EPS
Wall Street analysts forecast that Phreesia (PHR - Free Report) will report quarterly loss of -$0.07 per share in its upcoming release, pointing to a year-over-year increase of 77.4%. It is anticipated that revenues will amount to $116.45 million, exhibiting an increase of 14% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
In light of this perspective, let's dive into the average estimates of certain Phreesia metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts expect 'Revenus- Subscription and related services' to come in at $55.27 million. The estimate indicates a change of +13.7% from the prior-year quarter.
It is projected by analysts that the 'Revenus- Network solutions' will reach $33.25 million. The estimate points to a change of +17.9% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Revenus- Payment processing fees' of $27.90 million. The estimate points to a change of +10.3% from the year-ago quarter.
The consensus estimate for 'Average healthcare services Clients' stands at 4,475 . Compared to the present estimate, the company reported 4,169 in the same quarter last year.
Analysts predict that the 'Patient payment volume' will reach $1.18 billion. Compared to the present estimate, the company reported $1.09 billion in the same quarter last year.
View all Key Company Metrics for Phreesia here>>>Shares of Phreesia have demonstrated returns of +20.7% over the past month compared to the Zacks S&P 500 composite's +1.9% change. With a Zacks Rank #3 (Hold), PHR is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .